Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 640 GBX -0.62%
Market Cap: 771.2m GBX

Relative Value

The Relative Value of one OXB stock under the Base Case scenario is hidden GBX. Compared to the current market price of 640 GBX, Oxford BioMedica PLC is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OXB Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
31
vs Industry
70
Median 3Y
3.8
Median 5Y
4.5
Industry
7.9
Forward
4.6
vs History
vs Industry
10
Median 3Y
-8.8
Median 5Y
-8.8
Industry
24
Forward
-20.8
vs History
vs Industry
4
Median 3Y
-9.3
Median 5Y
-7.5
Industry
21.6
vs History
vs Industry
8
Median 3Y
-6.9
Median 5Y
-5.4
Industry
23.7
vs History
1
vs Industry
20
Median 3Y
5.4
Median 5Y
6.2
Industry
3.4
vs History
30
vs Industry
58
Median 3Y
3.8
Median 5Y
4.4
Industry
8.3
Forward
4.9
vs History
31
vs Industry
41
Median 3Y
8.3
Median 5Y
9.4
Industry
10.3
vs History
vs Industry
15
Median 3Y
-19.6
Median 5Y
-10.3
Industry
6.7
Forward
133.6
vs History
vs Industry
13
Median 3Y
-9.5
Median 5Y
-9.5
Industry
7.2
Forward
-30.9
vs History
vs Industry
4
Median 3Y
-9.4
Median 5Y
-7.9
Industry
8.2
vs History
vs Industry
11
Median 3Y
-14.4
Median 5Y
-12.2
Industry
6.7
vs History
30
vs Industry
44
Median 3Y
2.5
Median 5Y
3.2
Industry
5.7

Multiples Across Competitors

OXB Competitors Multiples
Oxford BioMedica PLC Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
UK
Oxford BioMedica PLC
LSE:OXB
771.2m GBP 5.1 -20.8 -124.2 -26.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 111 463.2 -162 126.7 -196 873.6 -194 627
US
Abbvie Inc
NYSE:ABBV
394.1B USD 6.6 167.8 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
168.9B USD 4.7 24.1 17.5 17.5
US
Gilead Sciences Inc
NASDAQ:GILD
148.2B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
111B USD 9.5 30.2 22.1 23.1
US
Epizyme Inc
F:EPE
94.1B EUR 2 065.3 -527 -573.9 -558.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
72.9B USD 5.1 15.9 15.1 17.1
AU
CSL Ltd
ASX:CSL
87.9B AUD 3.8 19.5 13.1 16.3
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
54.7B USD 17 1 256.1 165.2 200.4
NL
argenx SE
XBRU:ARGX
47B EUR 15.2 35.7 61.8 63.5
P/S Multiple
Revenue Growth P/S to Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average P/S: 3 101 236.4
5.1
31%
0.2
FR
Pharnext SCA
OTC:PNEXF
34 111 463.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
5%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.5
10%
0.9
US
E
Epizyme Inc
F:EPE
2 065.3
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17
46%
0.4
NL
argenx SE
XBRU:ARGX
15.2
49%
0.3
P/E Multiple
Earnings Growth PEG
UK
Oxford BioMedica PLC
LSE:OXB
Average P/E: 195.9
Negative Multiple: -20.8
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 126.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.8
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.1
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
9%
1.8
AU
CSL Ltd
ASX:CSL
19.5
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 256.1
N/A N/A
NL
argenx SE
XBRU:ARGX
35.7
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBITDA: 40.4
Negative Multiple: -124.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 873.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.5
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.9 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.1
11%
1.4
AU
CSL Ltd
ASX:CSL
13.1
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
165.2
N/A N/A
NL
argenx SE
XBRU:ARGX
61.8
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
UK
Oxford BioMedica PLC
LSE:OXB
Average EV/EBIT: 46.7
Negative Multiple: -26.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 627 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.5
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.1
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -558.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
13%
1.3
AU
CSL Ltd
ASX:CSL
16.3
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
200.4
N/A N/A
NL
argenx SE
XBRU:ARGX
63.5
N/A N/A